Swedish Orphan Biovitrum AB · OMXSTO:SOBI
Swedish Orphan Biovitrum AB — FY2010 Earnings Presentation
18 slides from Swedish Orphan Biovitrum AB's earnings presentation, Feb 23, 2011
Slide 1: Full Year 2010
Full Year 2010 February 23, 2011
Slide 2: Disclaimer
DISCLAIMER In order to utilize the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995, Swedish Orphan Biovitrum is providing the following cautionary statement. This presentation contains forward- looking statements with respect to the financial condition,
Slide 3: Executive Management Team
Executive Management Team • Kennet Rooth, CEO (pro term) • Lars Sandström, CFO • Göran Arvidson, VP Mergers & Acquisitions • Anders Edvell, VP Marketing & Sales • Peter Edman, VP R&D • Stefan Fraenkel, VP Business Development • Åsa Stenqvist, VP IR & Communication (pro term) • Lena Nyström, VP Opera
Slide 4: Summary Q4 2010
Summary Q4 2010 • Net sales declined 15% to SEK 465.0 M • Sales, excluding Tracleer® and milestone revenues, increased by 3% at CER • EBITA, excl. non-recurring items, was SEK 192.2 M • Sales rights for Mimpara® was sold back to Amgen • Core EPS was 0.60 4
Slide 5: January – December 2010
January – December 2010 • Net sales declined 7.7% to SEK 1 906.7 M (2 065.6) • Sales, excluding Tracleer® and milestone revenues, increased by 2% at CER • EBITA, excl. non-recurring items, increased to SEK 371.9 M (273.6) • Sales rights for Mimpara® were sold back to Amgen • Core EPS was 1.87 (0.84)
Slide 6: Revenues by product
Revenues by product Oct 1 - Dec 31 Jan 1 - Dec 31 CER Pro forma CER CER Pro forma CER Amounts in SEK million 2010 2010 2009 change 2010 2010 2009 change ReFacto 157.5 158.7 124.3 28% 587.1 593.5 631.9 -6% of which Manufacturing revenues 119.9 119.9 69.2 73% 388.0 388.0 376.5 3% of which Co-promotion
Slide 7: Product revenues by region
Product revenues by region (excl. ReFacto manufacturing, royalty and milestones) Oct 1 - Dec 31 Jan 1 - Dec 31 CER Pro forma CER CER Pro forma CER Amounts in SEK million 2010 2010 2009 change 2010 2010 2009 change Nordic 103.0 109.4 129.7 -16% 450.4 473.3 511.9 -8% Europe 140.5 156.6 156.1 0% 551.3
Slide 8: Income
Income Oct 1 - Dec 31 Jan 1 - Dec 31 Pro forma Pro forma Amounts in SEK million 2010 2009 change 2010 2009 change Total revenues 465,0 546,1 -15% 1 906,7 2 065,6 -8% Cost of goods and services sold -151,8 -166,5 -9% -685,7 -664,3 3% Gross profit 313,2 379,6 -17% 1 221,0 1 401,3 -13% Sales and admini
Slide 9: Summary Q4 2010
Summary Q4 2010 • Sales, excluding Tracleer® and milestone revenues, increased 3% at CER. • EBITA, excl. non-recurring items, was SEK 192.2 M • Sales rights for Mimpara® was sold back to Amgen 9
Slide 10: Kennet Rooth, CEO
Kennet Rooth CEO
Slide 11: Product sales and launches
Product sales and launches • Americas • Europe outside the Nordics Orfadin® sales demonstrated a sharp European environment showed signs of increase 30% (F.Y. CER) improvement at the end of 2010 • Increased medical marketing • Regulatory approvals • Increased screening of newborns • P&R decisions ma
Slide 12: Products and launches (cont´)
Products and launches (cont´) •Nordics •ROW New product launches New distributor in Korea • Ruconest® Expansion of distributor network a priority • Wilfact® • Yondelis®ova Sales commence in Northern Africa • Kineret®(re-launch) • Multiferon® First sales (Ammonaps®) in Russia late 2010 • Removab® Fir
Slide 13: R&D
R&D Indication Product/Project Partner Phase I Phase II Phase III Reg phase Hemophilia A rFVIIIFc BiogenIdec Hemophilia B rFIXFc BiogenIdec Prevent growth retardation in premature infants Kiobrina® CAPS Kineret® Pernicious anemia Nascobal® Strativa Activity Expected timing Kiobrina (prevent growth r
Slide 14: Pipeline products; Factor VIII and IX
Pipeline products; Factor VIII and IX • Sobi and Biogen Idec remain confident that we will deliver program data for rFIXFc and rFVIIIFc in the 2012 time frame as recruitment is on track. We plan to initiate global pediatric (< 12 years) trials for both programs in order to ensure rapid enrollment an
Slide 15: Kiobrina®
Kiobrina® • Phase II studies completed with positive results • Decision made to initiate a phase III study. Design discussed and agreed with EMA. PIP plan agreed with EMA • Discussion on study ongoing with FDA • FPFV planned for May • Study data available 2013 • Partnering in China represents an add
Slide 16: Business Development
Business Development • The Business Development function more than doubled; new experienced BD-Team in place - products - new distributors - expansion of existing territories for distribution products • Competence and capacity for M&A • Streamlining of existing distributor network • Three new deals
Slide 17: Summary
Summary • Seven new product launches • Three new business development deals in two months; continued intensive BD-activities • All phase III studies run according to plan • Sobi cost structure being addressed • Sobi´s long term objectives remain the same: Revenue SEK 5 billion, EBITA margin > 30 % i
Slide 18: www.sobi.com
@sobdl SWEDISH ORPHAN BIOVITRUM www.sobi.com 2011-02-23
Swedish Orphan Biovitrum — FY2010 Earnings Presentation on 6ix